Genmab A/S
NASDAQ:GMABBiotechnology
-$0.12 today
- Market cap
- $31.43B
- Beta
- 0.68
- P/E (TTM)
- 18.7
- EPS (TTM)
- $13.36
Volume 2.96M
Average 1.85M
GMAB Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Genmab A/SNASDAQ: GMAB
Gross Margin · Q2 FY2026 · quarter ended Jun 2026
Gross margin narrows to 92.7%
Gross margin was 92.7% in Q2 FY2026, down 1.1 pp from a year earlier. On a trailing-twelve-month basis it was 93.0%. Over 3 fiscal years it narrowed by 8.3 pp.
Context
- Gross margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 91.7%
- Year-over-year change
- —
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 91.7% | — |
| FY2024 | 2024-12-31 | 95.4% | -3.2pp |
| FY2023 | 2023-12-31 | 98.6% | -1.4pp |
| FY2022 | 2022-12-31 | 100.0% | +0.0pp |
| FY2021 | 2021-12-31 | 100.0% | — |
Gross Margin vs competitors
How GMAB compares with its peers on the latest reported figures
- GMAB's LTM Jun 2026 gross margin of 93.0% is the 3rd highest of the 10 companies compared; the peer median is 88.1%.
- Over three fiscal years its change of -8.3 pp compares with a peer median of -2.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jul 2026 | 96.5% | -0.1 pp | -0.0 pp | |
| LTM Jun 2026 | 94.0% | -6.0 pp | -4.0 pp | |
| LTM Jun 2026 | 93.0% | — | -8.3 pp | |
| LTM Jun 2026 | 92.6% | -0.3 pp | -1.1 pp | |
| LTM Mar 2026 | 90.7% | -2.0 pp | -7.9 pp | |
| LTM Mar 2026 | 88.1% | +17.9 pp | +0.3 pp | |
| LTM Jun 2026 | 70.8% | -8.9 pp | -5.1 pp | |
| LTM Mar 2026 | 69.9% | +7.9 pp | -24.0 pp | |
| LTM Sep 2026 | 57.0% | -3.6 pp | +16.2 pp | |
| LTM Sep 2026 | 53.2% | +23.4 pp | — | |
| FY2025 | — | — | — | |
| Peer median (excluding GMAB) | 88.1% | -0.3 pp | -2.6 pp | |
Competitors are the stored peer set for GMAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · DKK | FY2022 Dec 2022 · DKK | FY2023 Dec 2023 · DKK | FY2024 Dec 2024 · DKK | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 8.42B | 14.51B | 16.47B | 21.53B | 3.72B |
| Cost of Revenue | 0 | 0 | 226M | 985M | 309.24M |
| Gross Profit | 8.42B | 14.51B | 16.25B | 20.54B | 3.41B |
| Gross Margin | 100.0% | 100.0% | 98.6% | 95.4% | 91.7% |
| Research & Development | 4.18B | 5.56B | 7.63B | 9.75B | 1.56B |
| Selling, General & Admin | 1.28B | 2.68B | 3.3B | 3.79B | 602.47M |
| Operating Expenses | 5.46B | 8.24B | 10.93B | 13.84B | 2.16B |
| Depreciation & Amortization | 248.99M | 362M | 293.62M | 413M | 71.06M |
| EBITDA | 4.18B | 7.35B | 6B | 9.7B | 1.34B |
| EBITDA Margin | 49.7% | 50.6% | 36.4% | 45.0% | 35.9% |
| Operating Income | 2.95B | 6.27B | 5.32B | 6.7B | 1.25B |
| Operating Margin | 35.1% | 43.2% | 32.3% | 31.1% | 33.6% |
| Interest Income | 197M | 324M | 939M | 995M | 138.11M |
| Interest Expense | 13M | 21M | 27M | 120M | 61.05M |
| Other Income / Expenses | 965M | 678M | 316M | 2.46B | (46.04M) |
| Income Before Tax | 3.92B | 6.95B | 5.64B | 9.16B | 1.2B |
| Pre-Tax Margin | 46.5% | 47.9% | 34.2% | 42.6% | 32.4% |
| Income Tax Expense | 961M | 1.49B | 1.29B | 1.32B | 241.19M |
| Net Income | 2.96B | 5.45B | 4.35B | 7.84B | 963.76M |
| Net Margin | 35.1% | 37.6% | 26.4% | 36.4% | 25.9% |
| EPS (Basic) | 4.52 | 8.34 | 6.60 | 12.14 | 1.55 |
| EPS (Diluted) | 4.48 | 8.26 | 6.60 | 12.14 | 1.54 |
| Weighted Avg Shares | 653.96M | 653.87M | 659.15M | 646.33M | 621.51M |
| Weighted Avg Shares (Diluted) | 660.46M | 660.1M | 659.15M | 646.33M | 626.92M |
Genmab A/S
NASDAQ:GMAB
Intrinsic Alpha fair value
Locked
Current Price
$50.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.